Necroptosis

Why necroptosis matters

• It rewrote the definition of necrosis. For a century, necrosis was taught as passive, accidental death — the messy alternative to tidy apoptosis. The discovery that a specific kinase pathway (RIPK1→RIPK3→MLKL) executes it, and that a small molecule (necrostatin-1) can block it, converted necrosis into a regulated, druggable program. Necroptosis is now recognized alongside apoptosis and pyroptosis as a core mode of regulated cell death.
• It is an antiviral trap. Viruses that block caspase-8 to keep their host cell alive — cowpox's CrmA, and caspase-inhibiting herpesviruses and poxviruses — inadvertently license necroptosis, which kills the infected cell anyway. Murine cytomegalovirus fights back with vIRA (protein M45), a RHIM-containing decoy that blocks RIPK3, evidence of a genuine host-pathogen arms race centered on this pathway.
• It drives ischemia-reperfusion injury. Much of the tissue damage after a heart attack or stroke happens not during the block but during reperfusion, when RIPK3/MLKL-dependent necroptosis kills stressed cells. RIPK3-knockout and MLKL-knockout mice show markedly reduced infarct size, making the pathway a target for cardioprotection and neuroprotection.
• It is inflammatory by design. Unlike apoptosis, which is engineered to be silent, necroptosis is engineered to shout: the ruptured membrane releases DAMPs — HMGB1, ATP, IL-33, mitochondrial DNA, and pre-formed IL-1α — that recruit and activate immune cells. This makes it useful against pathogens but harmful in sterile inflammatory disease.
• RIPK1 inhibitors are in the clinic. Building on necrostatin-1, optimized RIPK1 kinase inhibitors from several pharma programs are in clinical trials for amyotrophic lateral sclerosis, Alzheimer's disease, psoriasis, rheumatoid arthritis, and ulcerative colitis — indications where chronic necroptotic inflammation is implicated.
• It shaped our understanding of caspase-8's day job. The greatest surprise of the field was that caspase-8, long seen only as an apoptosis initiator, has an equally essential job as the brake on necroptosis. Its embryonic-lethal knockout is rescued entirely by deleting RIPK3 or MLKL — proving that keeping necroptosis off is what caspase-8 is really for during development.
• It bridges cell biology and immunology. Because necroptosis converts a quiet cell into an immune alarm, it sits at the interface of cell death, innate immunity, and inflammation — and is being explored to make otherwise 'cold' tumors immunogenic by forcing them to die in a pro-inflammatory way.

Common misconceptions

• Necroptosis is just necrosis with a nicer name. No — the morphology is necrotic (swelling, rupture, spill), but the cause is a defined molecular program. Passive necrosis has no dedicated machinery and cannot be blocked by a drug; necroptosis is executed by RIPK3 and MLKL and is completely prevented by deleting either one. The shared morphology is the endpoint, not the mechanism.
• MLKL is a kinase that phosphorylates the membrane. MLKL is a pseudokinase — it retains the kinase fold but has lost catalytic residues and does not transfer phosphate. It is the substrate, not the enzyme: RIPK3 phosphorylates MLKL, and MLKL then kills by a purely physical mechanism — inserting its four-helix bundle into the lipid bilayer to form a pore.
• RIPK1 is always required. RIPK1 kinase activity nucleates the classic TNF-driven pathway, but RIPK3 can be activated independently of RIPK1 through other RHIM-containing sensors — TRIF (from TLR3/TLR4) and ZBP1/DAI (a Z-nucleic-acid sensor for viral genomes). In those routes RIPK1 can even be dispensable or inhibitory, so 'RIPK1 is the trigger' is only true for the TNFR1 branch.
• Caspase-8 only promotes death. Counter-intuitively, in the necroptosis context caspase-8 is pro-survival: by cleaving RIPK1 and RIPK3 it prevents a far more damaging, inflammatory death. This is why caspase-8-deficient mice die of runaway necroptosis, not of too little cell death.
• zVAD-fmk protects cells. The pan-caspase inhibitor zVAD-fmk blocks apoptosis, but in cells poised for necroptosis it does the opposite — by inhibiting caspase-8 it unleashes the RIPK3–MLKL program. Many early 'caspase-independent death' observations were unrecognized necroptosis provoked by the very inhibitor meant to prevent death.
• Every cell can undergo necroptosis. The pathway requires RIPK3 and MLKL expression, and many cell types silence RIPK3 (for example by promoter methylation, common in cancer). A cell lacking RIPK3 simply cannot necroptose no matter how much caspase-8 is inhibited — which is one way tumors evade this death route.

How necroptosis works

The best-characterized trigger is TNF-α binding TNFR1, the same receptor that can also drive survival or apoptosis — the outcome depends on which complex assembles. Ligated TNFR1 first builds membrane-bound complex I (TRADD, RIPK1, TRAF2/5, and the E3 ligases cIAP1/2 and LUBAC), where RIPK1 is heavily poly-ubiquitinated and signals cell survival through NF-κB. If that ubiquitin scaffold is stripped — by deubiquitinases like CYLD or by loss of cIAPs — RIPK1 is released into the cytosol to form complex II. Complex II has two fates. With active caspase-8 (in a heterodimer with cFLIP_L, scaffolded by FADD), RIPK1 and RIPK3 are cleaved and the cell dies by apoptosis or survives. When caspase-8 is inhibited, that brake fails and necroptosis proceeds.

Freed from cleavage, RIPK1 recruits RIPK3 through their RHIM domains — short RIP homotypic interaction motifs (the IQIG core in RIPK1, VQVG in RIPK3). RHIM–RHIM contacts template the two kinases into a stacked cross-β amyloid fiber, the necrosome, confirmed by solid-state NMR to adopt a serpentine β-sheet fold. This polymerization is not incidental — it clusters RIPK3 molecules densely enough to trans-autophosphorylate at human Ser227, generating the specific docking surface for the next and final player. RIPK1's kinase activity, blocked by necrostatin-1, is what licenses this assembly in the TNF pathway; the RHIM sensors TRIF and ZBP1 can nucleate RIPK3 by the same amyloid mechanism without RIPK1.

The executioner is MLKL (mixed lineage kinase domain-like), a pseudokinase whose C-terminal pseudokinase domain acts as a latch on its N-terminal four-helix bundle. RIPK3 phosphorylates MLKL at human Thr357 and Ser358 (mouse Ser345). Phosphorylation springs the latch: MLKL undergoes a conformational change, oligomerizes into trimers and higher assemblies, and translocates to the plasma membrane. There the exposed four-helix bundle binds phosphatidylinositol phosphates in the inner leaflet and inserts, forming a cation-permeable pore. Sodium and calcium flood in, water follows by osmosis, the cell swells (oncosis), and the membrane finally ruptures — releasing HMGB1, ATP, IL-33, and mitochondrial DNA as DAMPs that ignite inflammation. From necrosome nucleation to lysis the program runs in minutes to a few hours, and unlike apoptotic MOMP, the MLKL pore is the direct physical cause of death.

Necroptosis vs apoptosis vs pyroptosis vs ferroptosis

Feature	Necroptosis	Apoptosis	Pyroptosis	Ferroptosis
Trigger	Death receptors / TLRs / ZBP1 with caspase-8 blocked	BH3-only proteins / death receptors	Inflammasomes (NLRP3, AIM2)	Iron-dependent lipid peroxidation
Core executioners	RIPK1, RIPK3, MLKL	Caspases-3/7/8/9	Caspase-1/-11, gasdermin D	None (lipid radical chemistry)
Caspase involvement	None (caspase-8 inhibits it)	Central (caspases are the machinery)	Inflammatory caspases	None
Membrane fate	Swells, ruptures (MLKL pore)	Intact, blebs outward	Gasdermin pores, lyses	Lipid peroxide-driven rupture
Inflammation	High (DAMPs: HMGB1, ATP, IL-33)	Silent (anti-inflammatory)	Very high (IL-1β, IL-18)	Variable (oxidized lipids signal)
Role vs pathogens	Backup when virus blocks caspases	Immune-mediated killing, homeostasis	Alarm on cytosolic PAMPs	Not a primary immune route
Drug target	RIPK1/RIPK3 (necrostatins)	BCL-2 (venetoclax)	NLRP3 (MCC950)	GPX4 (RSL3, erastin)

The necrosome pathway step by step

Stage	Molecular event	Key players
1. Receptor ligation	TNF-α binds TNFR1; complex I forms and signals survival via NF-κB	TNF, TNFR1, TRADD, TRAF2/5, cIAP1/2, LUBAC
2. Complex II formation	Deubiquitination (CYLD) releases RIPK1 into a cytosolic death complex	RIPK1, FADD, caspase-8, cFLIPL
3. Checkpoint	Caspase-8/cFLIPL cleaves RIPK1/RIPK3 — unless caspase-8 is blocked	Caspase-8, cFLIPL, FADD
4. Necrosome assembly	RIPK1–RIPK3 RHIM–RHIM polymerization into an amyloid fiber	RIPK1 (IQIG), RIPK3 (VQVG)
5. RIPK3 activation	Trans-autophosphorylation at human Ser227 creates MLKL docking site	RIPK3 kinase domain
6. MLKL phosphorylation	RIPK3 phosphorylates MLKL Thr357/Ser358, releasing the 4HB latch	RIPK3, MLKL pseudokinase domain
7. Pore formation	Phospho-MLKL trimerizes, binds PIPs, inserts, and drills a cation pore	MLKL four-helix bundle, PIP2
8. Lysis	Na⁺/Ca²⁺ influx, osmotic swelling, membrane rupture, DAMP release	Oncosis; HMGB1, ATP, IL-33, mtDNA

Famous experiments and history

• Necrostatin-1 and the naming (2005). Alexei Degterev, Junying Yuan, and colleagues screened for compounds that blocked a caspase-independent, TNF-induced 'necrotic' death without touching apoptosis, and found necrostatin-1. That a specific small molecule could prevent this death proved it was a regulated program — which they named necroptosis in Nature Chemical Biology. Nec-1's target was later shown to be RIPK1 kinase.
• RIPK3 identified as essential (2009). Three groups — those of Xiaodong Wang, Zhenggang Liu, and Francis Chan — independently showed in 2009 that RIPK3 is the switch that determines whether cells die by necroptosis, and that RIPK1–RIPK3 form the necrosome. RIPK3-deficient cells and mice were resistant to programmed necrosis but normal for apoptosis.
• MLKL discovered as the executioner (2012). Two 2012 papers — Jiahuai Han's group and a Walter and Eliza Hall Institute team including James Murphy and John Silke — identified MLKL as the RIPK3 substrate that carries out death, using a small-molecule (necrosulfonamide) and phospho-site mapping. Later work showed MLKL is a pore-forming executioner, not a signaling kinase.
• Caspase-8 knockout rescue (2011). Mouse genetics settled the pathway's logic: Casp8−/− and Fadd−/− mice die around embryonic day 10.5, but the groups of Oberst and Green and of Kaiser and Mocarski showed that co-deleting Ripk3 — and later Mlkl — fully rescues them to viable, fertile adults. This proved caspase-8's essential developmental role is to restrain RIPK3–MLKL necroptosis.
• The viral arms race (vIRA / M45). Murine cytomegalovirus protein M45 (vIRA) carries a RHIM that binds and disables RIPK3, blocking necroptosis so the virus can persist. A single point mutation in that RHIM renders the virus attenuated in wild-type mice but not in RIPK3-deficient mice — a clean genetic demonstration that necroptosis is a bona fide antiviral defense the virus must actively counter.